Investigating the impact of hyperglycemia on modulating T cell populations in breast cancer
研究高血糖对调节乳腺癌 T 细胞群的影响
基本信息
- 批准号:10750137
- 负责人:
- 金额:$ 4.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AntigensAntitumor ResponseApplications GrantsAutomobile DrivingBioenergeticsBioinformaticsBiological AssayBiological ModelsBreast Cancer PatientBreast Cancer TreatmentBreast Cancer therapyBreast CarcinomaCD8-Positive T-LymphocytesCD8B1 geneCancer ControlClinicalCombined Modality TherapyCompetenceDataDiabetes MellitusDiseaseDoctor of PhilosophyEnvironmentErinaceidaeFOXP3 geneFemaleFoundationsFunctional disorderGenesGenetically Engineered MouseGlucose IntoleranceGlycolysisGoalsHyperglycemiaImmuneImmunologicsImmunosuppressionImmunotherapyImpairmentInfiltrationInvestigationLymphocyteMalignant NeoplasmsMammary NeoplasmsMammary TumorigenesisMentorsMentorshipMetabolicMetabolismMetforminModelingMorbidity - disease rateNomenclatureNon-Insulin-Dependent Diabetes MellitusOncologistOutcomePathogenesisPatientsPeripheralPhenotypePhysiciansPopulationPre-Clinical ModelPrimary NeoplasmProcessProductionPrognosisReadinessRegulatory T-LymphocyteReportingReproducibilityResearchResearch Project GrantsRiskRoleScientistSolidT-LymphocyteT-Lymphocyte SubsetsTechniquesTrainingType 2 diabeticUnited StatesWomanWorkbreast cancer progressioncancer infiltrating T cellscareercytokinecytotoxicdiabeticdiabetic patientexhaustionglycemic controlimmunogenicitymalignant breast neoplasmmammarymarginalized populationmouse modelnovelpatient populationpatient subsetspre-clinicalprogramsresponseresponsible research conductsmoothened signaling pathwaystemtreatment and outcometreatment responsetriple-negative invasive breast carcinomatumortumor microenvironmenttumor-immune system interactionstumorigenic
项目摘要
PROJECT ABSTRACT
This grant application is for the F31-Diversity support of Courtney Swain during her MD-PhD training. The
research focus of this proposal is to establish a mechanism in which hyperglycemia and Hedgehog (Hh) signaling
conspire to modulate CD8+ T cell exhaustion and regulatory T cell (Treg) immunosuppression in triple-negative
breast cancer (TNBC). Breast cancer continues to threaten the lives of many women in the U.S. and worldwide
as it accounts for more than 30% of all female cancer cases. Additionally, type 2 diabetes mellitus (T2D) is a
highly prevalent morbidity and about a quarter of breast cancer patients are diabetic, which can increase
treatment complications and limit therapy options. TNBC tumors are immunologically “cold,” characterized by
the limited infiltration of cytotoxic populations and increased abundance of immunosuppressive constituents in
the primary tumor. Hyperglycemia in T2D pathogenesis has been implicated to impair CD8+ T cells, lymphocytes
critical in tumor killing and immunotherapy response, and their exhaustion process. Upon tumor challenge,
subsets of immunologically reactive TCF1+ stem-like and TCF1- transitory effector CD8+ T cells are generated.
These CD8+ T cell subsets have been found to be highly essential in tumor control despite their phenotype and
nomenclature of early exhaustion. Notably, hyperglycemia exacerbates dysregulated Hh signaling in breast
cancer. Initial investigations have revealed that hyperglycemia and Hh signaling may be cooperatively driving
dysfunctional CD8+ T cell exhaustion in the mammary tumor milieu. Additionally, the presence of Tregs during
mammary tumorigenesis correlates with poorer prognoses in TNBC. Supporting evidence in this proposal
underscores that both, Hh signaling and hyperglycemia, impair CD8+ T cell exhaustion and promote Treg
immunosuppression. However, the mechanisms by which these factors influence these key T cell populations
are unknown. Therefore, this proposal will apply unique model systems of Hh signaling and hyperglycemia to
delineate their roles in CD8+ T cell and Treg activity in TNBC. Findings will provide more relevance for
combination TNBC therapies, especially for the distinct patient population of diabetic breast cancer patients.
The proposed training plan for the PI is sponsored by her PhD mentor, Dr. Lalita Shevde-Samant. The goals of
the training plan are to provide the PI with: (i) a rigorous research project using distinctive pre-clinical models of
diabetes-associated breast cancer, novel genetically engineered mice, and tumor-immune crosstalk; (ii)
opportunities in developing immunologic and bioinformatic techniques and in expanding training in responsible
conduct of research, rigor, reproducibility, and principles of scientific integrity; and (iii) a scientifically enriching
and equipped environment essential for developing a successful career as an oncologist-scientist. Given this
project’s focus on the interaction of two major disease challenges of the U.S., breast cancer and diabetes, the
PI will have exemplary guidance and a solid foundation to develop into a very competent physician-scientist.
项目摘要
该赠款申请是在MD-PHD培训期间对Courtney Swain的F31多样性支持。这
该建议的研究重点是建立一种机制,高血糖和刺猬(HH)信号传导
合并调节三阴性的CD8+ T细胞耗尽和调节T细胞(TREG)免疫抑制
乳腺癌(TNBC)。乳腺癌继续威胁到美国和全球许多妇女的生命
因为它占所有女性癌症病例的30%以上。此外,2型糖尿病(T2D)是
高度普遍的发病率和大约四分之一的乳腺癌患者是糖尿病患者,可以增加
TNBC肿瘤在免疫学上是“冷”,其特征是
在
原发性肿瘤。 T2D发病机理中的高血糖已与CD8+ T细胞有关
对肿瘤杀伤和免疫疗法的反应至关重要及其疲惫过程。在肿瘤挑战时,
产生了免疫反应性TCF1+茎状和TCF1转换效应子CD8+ T细胞的子集。
这些CD8+ T细胞子集在肿瘤控制目的地中非常重要,它们的表型和
早期疲惫的命名法。值得注意的是,高血糖加剧了乳房中HH信号失调
癌症。最初的调查表明,高血糖和HH信号可能正在合作驱动
乳腺肿瘤环境中功能失调的CD8+ T细胞耗尽。另外,在
乳腺肿瘤发生与TNBC中较差的预后相关。该提议中的支持证据
强调HH信号传导和高血糖,都会损害CD8+ T细胞耗尽并促进Treg
免疫抑制。但是,这些因素影响这些关键T细胞种群的机制
是未知的。因此,该建议将应用HH信号传导和高血糖的独特模型系统
描述它们在TNBC中的CD8+ T细胞和Treg活性中的作用。调查结果将为
联合TNBC疗法,特别是针对糖尿病乳腺癌患者的不同患者群体。
PI的拟议培训计划由她的博士学位Lalita Shevde-Samant博士赞助。目标
培训计划将为PI提供:(i)使用独特的临床前模型的严格研究项目
糖尿病相关的乳腺癌,新型的基因工程小鼠和肿瘤免疫串扰; (ii)
开发免疫和生物信息学技术以及扩大负责任的培训的机会
进行研究,严格,可重复性和科学完整性原理的进行; (iii)科学丰富
以及为发展作为肿瘤学家科学家成功职业至关重要的设备环境。鉴于此
项目关注美国两种主要疾病挑战的相互作用,乳腺癌和糖尿病,即
PI将具有典范指导和坚实的基础,以发展成一个非常有能力的身体科学家。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Courtney A Swain其他文献
Courtney A Swain的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
P3H1通过ATF4/System Xc-轴抑制肾癌铁死亡和抗肿瘤免疫反应的作用及机制研究
- 批准号:82372704
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SLAM家族受体负调cDC1细胞活化和抗肿瘤免疫反应的机制研究
- 批准号:32330034
- 批准年份:2023
- 资助金额:221 万元
- 项目类别:重点项目
稀土金属催化吡啶邻位烷基区域选择性碳氢键硼化反应及其在抗肿瘤药物中的应用研究
- 批准号:22301222
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
泛素化酶KLHL6调控T细胞耗竭及抗肿瘤免疫反应的机制研究
- 批准号:32300764
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
SLC5A12通过组蛋白乳酸化调控膀胱癌三级淋巴结构削弱抗肿瘤免疫反应
- 批准号:82373337
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck
个体化疫苗免疫疗法联合抗 PD 1 抗体治疗复发性或转移性头颈部鳞状细胞癌
- 批准号:
10658577 - 财政年份:2023
- 资助金额:
$ 4.13万 - 项目类别:
Enhancing CAR T Cell Homing Through Glycoengineering
通过糖工程增强 CAR T 细胞归巢
- 批准号:
10577107 - 财政年份:2023
- 资助金额:
$ 4.13万 - 项目类别:
Toward translation of a plant virus-based in situ vaccination nanotechnology
基于植物病毒的原位疫苗接种纳米技术的转化
- 批准号:
10688114 - 财政年份:2022
- 资助金额:
$ 4.13万 - 项目类别:
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
下一代自体 TIL 癌症疗法:GMP 制造工艺的开发
- 批准号:
10685604 - 财政年份:2022
- 资助金额:
$ 4.13万 - 项目类别:
Toward translation of a plant virus-based in situ vaccination nanotechnology
基于植物病毒的原位疫苗接种纳米技术的转化
- 批准号:
10529016 - 财政年份:2022
- 资助金额:
$ 4.13万 - 项目类别: